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Background: Triggering receptor expressed on myeloid cells-1 (TREM-1)
is a receptor of the immunoglobulin superfamily expressed on the
surface of neutrophils and monocytes/macrophages. It plays an important
role during sepsis by amplifying the inflammatory response. Modulation
of TREM-1 through the administration of a short synthetic peptide (LR12)
increases survival during experimental sepsis. This study aimed to explore
the mechanisms by which LR12 prevented sepsis-induced cardiovascular
dysfunction.
Methods: We studied the effect of TREM-1 modulation by a synthetic
peptide LR12 (3 mg/kg) on MAP and blood lactate during experimental
sepsis (CLP). Aortic and mesenteric arterial vessels of these animals were
collected to study the vasoreactivity to phenylephrine (Phe) and
acetylcholine (Ach) ex vivo (Myograph). Alternatively, vasoreactivity was
studied in the vessels of healthy animals (with and without endothelial
lawyer) stimulated with LPS or with a specific agonist of TREM-1 (aTREM-
1, 10 μg/ml), with or without LR12 (20 mg/ml). The effect of LR12 on
arterial vessels was also studied through western blotting (eNOS, iNOS,
Akt, COX-1, COX-2) and qRT-PCR. Mouse lung microvascular endothelial
cells (LUMECs; CD146
+) were analyzed by flow cytometry, qRT-PCR, and
ELISA to decipher the effect of LR12 on LPS-induced endothelial
activation.
Results: CLP induced MAP decrease and lactate elevation were prevented
by the administration of LR12. Arterial vessels from septic animals treated
with LR12 showed better response to Phe and Ach compared with
controls. The reactivity of aortic and mesenteric vessels (contraction and
relaxation) stimulated in vitro with LPS or by aTREM-1 was altered: this
phenomenon was reversed by LR12. LR12 restored the phosphorylation of
Akt and eNOS while it reduced the activation of inducible pathways (iNOS,
COX-2). FACS analysis showed that TREM-1 is constitutively expressed by
LUMECs (CD146
+/VEGFR2
+). In vivo, the expression of Trem-1 was increased
in septic animals and was inducible in vitro upon stimulation with LPS.
Trem-1, Tnf-a and Il-6 expression was upregulated by LPS; once again LR12
attenuated this upregulation. Finally, the production of several cytokines
by LPS-stimulated LUMECs was decreased by LR12.
Conclusion: Here we show that TREM-1 is expressed on endothelial cells
from the aorta, mesenteric artery, and microvascular endothelial cells, and
that TREM-1 might be directly involved in endothelial dysfunction during
experimental sepsis.
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Background: In macrophages Toll-like receptor 4 (TLR4) is activated in
response to lipopolysaccharide (LPS) and induces proinflammatory cytokine
expression [1]. Therefore, mechanisms terminating proinflammatory gene
expression are important. Autophagy plays a central role in controlling
innate immune responses by lysosomal degradation of signaling proteins,
thus contributing to the resolution of inflammation [2]. Autophagic proteins
like p62 directly interact with molecules involved in the TLR4-signaling
pathway, but a correlation with the IRAK E3 ligase and scaffold protein
Pellino3 remains obscure [3,4]. Hence, we are interested in elucidating the
function of Pellino3 to prove our hypothesis that it is a key regulator in the
TLR4-signaling cascade [5].
Methods: We used the cecal ligation and puncture (CLP) mouse model
causing polymicrobial sepsis to analyze Pellino3 protein and mRNA
expression. Furthermore, we induced endotoxemia in RAW264.7 mouse
macrophages by LPS treatment to verify in vivo experiments. Lentiviral
Pellino3 knockdown in RAW264.7 macrophages was used for cytokine
measurements at mRNA level. To analyze potential Pellino3 binding
partners in TLR4-signaling by mass spectrometry (MS), we overexpressed
FLAG-tagged Pellino3 in RAW264.7 macrophages, treated cells for 3, 6
and 24 hours with LPS and immunoprecipitated Pellino3 via its FLAG-tag.
To consider Pellino3 degradation as a result of p62-mediated autophagy,
we transiently knocked down p62 by siRNA in RAW264.7 macrophages
and also pharmacologically blocked LPS-induced autophagy by
Bafilomycin A1.
Results: We demonstrated Pellino3 protein degradation in primary
CD11b
+ s p l e n o c y t e sa f t e r2 4h o u r sf ollowing CLP operation and
confirmed this in RAW264.7 macrophages after 24-hour LPS stimulation.
Knockdown of Pellino3 attenuates proinflammatory cytokines, for
example IL-6 mRNA, after 6 hours of LPS. Furthermore, we found by MS
and verifying immunoprecipitation experiments that p62 is a Pellino3
binding partner, thus targeting Pellino3 for degradation. In line, both p62
knockdown and Bafilomycin A1 treatment prevent Pellino3 degradation,
supporting an autophagic mechanism.
Conclusion: Our observations highlight a regulatory role of Pellino3 on
TLR4 signaling. Thus, antagonism of Pellino3 in the hyperinflammatory
Figure 1(abstract P48) LR12 protects from sepsis-induced hypotension. Evolution of mean arterial pressure (a) and norepinephrine requirements (b)
during the 24-hour study period. MAP was constantly higher and norepinephrine dose lower in LR12-treated animals than controls.
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stabilization of Pellino3 by inhibition of autophagy in the hypoinflammatory
phase of sepsis may improve immunity. In consideration of these two
conflictive sepsis phases, modulation of Pellino3 may provide a new strategy
for the development of a therapy approach in sepsis.
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Background: The multicomponent phagocytic NADPH oxidase produces
reactive oxygen species (ROS) after activation by microorganisms or
inflammatory mediators [1]. In the hypoinflammatory phase of sepsis,
macrophages are alternatively activated by contact with apoptotic cells or
their secretion products. This inhibits NADPH oxidase and leads to
attenuated ROS production [2] and furthermore contributes among others
to a hyporeactive host defense. Due to this immune paralysis, sepsis
patients suffer from recurrent and secondary infections [3]. We focused on
the catalytic subunit of NADPH oxidase, the transmembrane protein NOX2
[4]. We assume that after induction of sepsis the expression of NOX2 is
reduced and hence ROS production is decreased.
Methods: We induced polymicrobial sepsis in mice by cecal ligation and
puncture. The ability of peritoneal macrophages (PMs) to produce ROS was
determined by FACS via hydroethidine assay. NOX2 expression of PMs was
determined by western blot and qPCR. To elucidate the mechanism
causing mRNA destabilization, we performed in vitro experiments using
J774 macrophages. To obtain an alternatively activated phenotype,
macrophages were stimulated with conditioned medium from apoptotic
T cells (CM). By luciferase assays we figured out a 3’UTR-dependent
regulation of NOX2 mRNA stability. Assuming that a protein is involved in
the mRNA degradation, we performed a RNA pulldown with biotinylated
NOX2-3’UTR constructs followed by mass spectrometry. We verified the
role of SYNCRIP by siRNA approach. Additionally, we overexpressed NOX2
in J774 cells and analyzed the ROS production (w/wo CM treatment) by
FACS.
Results: We found an impaired expression of NOX2 at RNA and protein
level along with decreased ROS production after induction of sepsis in mice
as well as stimulating J774 macrophages with CM of apoptotic T cells. This is
due to a time-dependent NOX2 mRNA degradation depending on SYNCRIP,
a RNA-binding protein, which stabilizes NOX2 mRNA through binding to its
3’UTR under normal conditions. In line, knockdown of SYNCRIP also
decreases NOX2 mRNA expression. We assume that a CM-dependent
modification or degradation of SYNCRIP prevents its stabilizing function. As
the overexpression of NOX2 restores ROS production of CM-treated J774
cells, we assume that NOX2 expression is crucial for maintaining NADPH
activity during the hypoinflammatory phase of sepsis.
Conclusion: Our data imply a regulatory impact of SYNCRIP on NOX2
stability during the late phase of sepsis. Therefore, further understanding
of the regulation of NADPH oxidase could lead to the design of a therapy
to reconstitute NADPH oxidase function, finally improving immune
function in sepsis patients.
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Background: The ligand-activated transcription factor, peroxisome-
proliferator-activated receptor gamma (PPARg), has been shown to play an
essential role in immunosuppression during sepsis. PPARg is upregulated in
T cells of septic patients, sensitizing these cells to PPARg-dependent
apoptosis and thus contributing to T-cell depletion [1,2]. In the polymicrobial
cecum ligation and puncture (CLP) sepsis model in mice, both T-cell-specific
gene knockout (Lck-Cre PPARg
fl/fl) and systemic pharmacological PPARg
antagonism by GW9662 improved survival [3]. Because GW9662 was only
effective when applied 3 hours after CLP, we were interested to extend this
time frame. For this reason we characterized the kinetics of SPPARgMs when
administered before or in combination with the agonist thiazolidinedione,
rosiglitazone.
Methods: AP P A R g-dependent transactivation assay was used in HEK293T
cells. It is based on the vector pFA-PPARg-LBD-GAL4-DBD encoding the
hybrid protein PPARg-LBD-GAL4-DBD and the reporter vector pFR-Luc,
carrying a GAL4-responsive element in front of the Firefly luciferase gene.
These two vectors were co-transfected, in combination with a control
vector encoding Renilla luciferase (pRL-CMV) to normalize Firefly luciferase
activity for transfection efficiency. Following transfection, cells were
incubated with the SPPARgMs F-MOC and MCC-555 and the PPARg
antagonist GW9662 for different times (2 to 48 hours) and at increasing
doses (0.01 to 10 μM), with or without rosiglitazone (0.01 to 10 μM).
Transactivation was analyzed using a 96-well plate format.
Results: Rosiglitazone transactivated PPARg in a time-dependent and dose-
dependent manner, the response gradually increasing to a maximum at
48 hours with 10 μM. Low concentrations (0.01 to 0.1 μM) of SPPARgMs
F-MOC and MCC-555 and the PPARg antagonist GW9662 all exerted dose-
independent antagonistic effects at an early incubation time point (2 hours).
From 10 hours onwards, MCC-555 and GW9662, given alone, both exerted
PPARg agonistic effects, MCC-555 in parallel to responses to rosiglitazone,
but GW9662 with characteristics of partial antagonism. F-MOC showed no
dose-dependent effect at any concentration at later time points. Only
GW9662 (1 to 10 μM) was able to inhibit rosiglitazone (0.1 to 1 μM)-induced
PPARg transactivation after 10 hours.
Conclusion: Our kinetic analysis reveals clear differences in the
modulatory characteristics of PPARg inhibitors, with previously unreported
early inhibitory effects and late agonistic or partial agonistic activity. New
SPPARgMs with extended inhibitory activity may prove useful in the
therapy of sepsis.
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